The role of angiogenesis in rheumatoid arthritis: Recent developments

Annals of the Rheumatic Diseases

Volumn 59, Issue SUPPL. 1, 2000, Pages

  Koch, A E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOSTATIN; CELL ADHESION MOLECULE; CHEMOKINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; ENDOGLIN; ENDOSTATIN; EPHRIN; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GLYCOCONJUGATE; PACLITAXEL; PROSTAGLANDIN E2; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; THALIDOMIDE; THROMBOSPONDIN; VASCULOTROPIN;

ANGIOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE COURSE; DISEASE MARKER; DRUG TARGETING; HUMAN; IMAGING; MONITORING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS;

EID: 0033758575     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.suppl_1.i65     Document Type: Conference Paper

References (114)

1. Angiogenesis in rheumatoid arthritis: Pathogenic and clinical significance
2. Review: Angiogenesis: Implications for rheumatoid arthritis
3. Synovial membrane cellularity and vascularity
4. Angiogenesis in pannus formation
5. Vascular endothelium, cytokines, and the pathogenesis of inflammatory synovitis
6. Angiogenesis in arthritis: Role in disease pathogenesis and as a potential therapeutic target
7. Angiogenesis in inflammatory disease
8. Angiogenesis and arthritis
9. Angioneogenesis in rheumatoid arthritis
10. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts
11. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells
12. Defective angiogenesis in mice lacking Endoglin
13. Increased synovial expression of TGF-β receptor endoglin and TGF-β1 in rheumatoid arthritis
14. Molecular and biological properties of vascular endothelial growth factor
15. The role of vascular endothelial growth factor in pathological angiogenesis
16. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis
17. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta
18. Vascular endothelial growth factor in patients with rheumatoid arthritis
19. Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue
20. Serum concentrations of vascular endothelial growth factor in collagen diseases
21. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): Specific upregulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid
22. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis
23. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis
24. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1-induced vascular endothelial growth factor secretion by human synovial fibroblasts
25. New developments in angiogenesis: A major mechanism for tumor growth and target for therapy
26. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis
27. Angiogenesis, apoptosis and vascularity in early arthritis
28. CD 40 engagement on synovial fibroblast upregulates expression of vascular endothelial growth factor
29. Contrasting effects of TGFβ1 and BMP-2/4; regulators of vascular endothelial growth factor in rheumatoid arthritis
30. Endothelial cell decay-accelerating factor (DAF) is induced by vascular endothelial growth factor (VEGF), is cytoprotective against activated complement and may be involved in regulating endothelial cell proliferation in chronic synovitis
31. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: Reduction of vascular endothelial growth factor (VEGF)
32. Angiogenesis inhibitor suppresses arthritis and preserves from bone destruction in a new transgenic mouse model of RA
33. Blockade of vascular endothelial growth factor activity attenuates murine collagen-induced arthritis
34. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins
35. Adhesion molecule expression in human synovial tissue
36. Requirement of vascular integrin alpha v beta 3 for angiogenesis
37. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
38. Altered integrin expression in rheumatoid synovial lining type B cells: In vitro cytokine regulation of alpha 1 beta 1, alpha 6 beta 1, and alpha v beta 5 integrins
39. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist
40. The effect of SB 2730005, an orally active, non-peptide αvβ3 vitronectin receptor antagonist in the adjutant arthritic rat
41. Targeted apoptosis of synovial neovasculature in murine collagen-induced arthritis
42. The chemokine system: Redundancy for robust outputs
43. Interleukin-8 as a macrophage-derived mediator of angiogenesis
44. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis
45. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha
46. Fractalkine, a novel angiogenic chemokine in rheumatoid arthritis
47. Fractalkine, a novel chemokine in rheumatoid arthritis and rat adjuvant induced arthritis
48. A new class of membrane-bound chemokine with a CX3C motif
49. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1
50. Missing link in angiogenesis
51. Le(y)/H: And endothelial-selective, cytokine inducible angiogenic mediator
52. 4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis
53. Basic biochemistry of cell surface carbohydrates and aspects of the tissue distribution of histo-blood group ABH and related glycosphingolipids
54. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung
55. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity
56. Lipopolysaccharides of Helicobacter pylori strains P466 and MO19: Structures of the O antigen and core oligosaccharide regions
57. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
58. Requisite role of Angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
59. Increased vascularization in mice overexpressing angiopoietin-1
60. Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by Secretion-Trap Expression Cloning
61. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4
62. Vasculogenesis, angiogenesis, and growth factors: Ephrins enter the fray at the border
63. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
64. Tumor angiogenesis - New drugs on the block
65. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth
66. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma
67. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis
68. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells
69. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
70. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
71. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity
72. Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis
73. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin
74. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells
75. Angiostatin induces and sustains dormancy of human primary tumors in mice
76. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
77. Angiostatin binds ATP synthase on the surface of human endothelial cells
78. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
79. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
80. Identification of an inhibitor of neovascularization from cartilage
81. A cartilage-derived inhibitor of neovascularization and metalloproteinases
82. Inhibition of neovascularization by a cartilage factor
83. Inhibition of tumor angiogenesis mediated by cartilage
84. Isolation of a cartilage factor that inhibits tumor neovascularization
85. Shark cartilage contains inhibitors of tumor angiogenesis
86. Troponin I is present in human cartilage and inhibits angiogenesis
87. Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent
88. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle
89. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470)
90. Angiogenesis inhibition suppresses collagen arthritis
91. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis
92. Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2
93. Immunomodulation by thalidomide and thalidomide analogues
94. The effect of thalidomide and 2 analogs on collagen induced arthritis
95. Taxol involution of collagen-induced arthritis: Ultrastructural correlation with the inhibition of synovitis and neovascularization
96. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol
97. Role of prostaglandin E1 and copper in angiogenesis
98. Cyclooxygenase gene expression in inflammation and angiogenesis
99. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants
100. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
101. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis
102. Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization?
103. Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis
104. Synovial fluid CD146 (MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis
105. Serum levels of angiogenic growth factors in patients with early synovitis
106. Eleveated serum vascular endothelial growth factor in early arthritis
107. Angiogenesis, apoptosis and vascularity in early arthritis
108. Angiogenesis markers for predicting outcomes in rheumatoid arthritis
109. Specific targeting of activated endothelium in rat adjuvant arthritis with a 99mTc-radiolabeled E-selectin-binding peptide
110. Quantitative assessment of the rheumatoid synovial microvascular bed by gadolinium-DTPA enhanced magnetic resonance imaging
111. Evaluation of pannus and vascularization of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis by high-resolution ultrasound (multidimensional linear array)
112. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA
113. Antiangiogenic gene therapy
114. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate